{"id":"sofosbuvir-velpatasvir","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":{"setId":"17ffc094-8ca7-45d2-80d8-fd043bc9a221","title":"VOSEVI (SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR) TABLET, FILM COATED [GILEAD SCIENCES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sofosbuvir is a nucleotide analog that acts as a chain terminator of the HCV RNA-dependent RNA polymerase (NS5B), preventing viral RNA synthesis. Velpatasvir is a non-structural protein 5A (NS5A) inhibitor that disrupts viral replication and assembly. Together, this fixed-dose combination provides direct-acting antiviral activity against multiple HCV genotypes.","oneSentence":"Sofosbuvir inhibits hepatitis C virus NS5B polymerase while velpatasvir inhibits NS5A protein, together blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:56.686Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, all genotypes"},{"name":"HCV in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT03520660","phase":"PHASE4","title":"People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2018-10-19","conditions":"Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases","enrollment":121},{"nctId":"NCT04075916","phase":"PHASE2","title":"A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2021-06-22","conditions":"End Stage Renal Disease","enrollment":201},{"nctId":"NCT06953479","phase":"PHASE4","title":"Implementing Low-Barrier HCV Treatment in a Jail Setting","status":"RECRUITING","sponsor":"Lifespan","startDate":"2025-06-11","conditions":"HEPATITIS C (HCV), Incarceration, Injection Drug Use","enrollment":40},{"nctId":"NCT05653232","phase":"NA","title":"Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-04-19","conditions":"HCV","enrollment":120},{"nctId":"NCT05140941","phase":"PHASE4","title":"Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy","status":"RECRUITING","sponsor":"Catherine Anne Chappell","startDate":"2022-04-04","conditions":"Hepatitis C, Chronic, Pregnancy; Infection","enrollment":100},{"nctId":"NCT03383419","phase":"PHASE2","title":"Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients","status":"RECRUITING","sponsor":"Baylor Research Institute","startDate":"2018-03-20","conditions":"Heart Failure","enrollment":15},{"nctId":"NCT07037277","phase":"PHASE3","title":"C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV","status":"RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-06-02","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection","enrollment":880},{"nctId":"NCT03222531","phase":"PHASE2","title":"Expanding the Pool in Orthotopic Heart Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mary E. Keebler, MD","startDate":"2017-08-01","conditions":"Hepatitis C, Heart Transplant, Cardiac Transplant","enrollment":20},{"nctId":"NCT06868264","phase":"PHASE3","title":"C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-07","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION","enrollment":880},{"nctId":"NCT05248919","phase":"NA","title":"Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan","status":"ENROLLING_BY_INVITATION","sponsor":"Queen Mary University of London","startDate":"2023-06-01","conditions":"Hepatitis C","enrollment":318},{"nctId":"NCT03809533","phase":"PHASE2","title":"The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amit D Tevar, MD","startDate":"2019-05-29","conditions":"Kidney Transplantation, Hepatitis C","enrollment":30},{"nctId":"NCT03981445","phase":"NA","title":"Integrated HIV Prevention and HCV Care for PWID","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2019-11-14","conditions":"HIV Prevention, HCV, Opioid Use","enrollment":446},{"nctId":"NCT03819322","phase":"PHASE2","title":"The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients","status":"COMPLETED","sponsor":"Fernanda P Silveira, MD, MS","startDate":"2019-08-15","conditions":"Liver Transplant, Hepatitis C","enrollment":73},{"nctId":"NCT03949764","phase":"PHASE4","title":"The Kentucky Viral Hepatitis Treatment Study","status":"COMPLETED","sponsor":"Jennifer Havens","startDate":"2019-09-23","conditions":"Hepatitis C, Opioid-Related Disorders, Injection Drug Use","enrollment":374},{"nctId":"NCT07098481","phase":"PHASE4","title":"Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-09-01","conditions":"Hepatitis C Virus Infection","enrollment":576},{"nctId":"NCT06159504","phase":"EARLY_PHASE1","title":"Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania","status":"RECRUITING","sponsor":"Médecins du Monde","startDate":"2024-10-03","conditions":"Hepatitis C, RDT","enrollment":3040},{"nctId":"NCT03987503","phase":"PHASE4","title":"The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-07-01","conditions":"Hepatitis C, Chronic","enrollment":87},{"nctId":"NCT03112044","phase":"EARLY_PHASE1","title":"Lung Transplant HCV, Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2017-09-19","conditions":"Lung Transplant Infection, Hepatitis C","enrollment":26},{"nctId":"NCT06829966","phase":"","title":"Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-05-13","conditions":"Intestinal Microbiota Between Different Groups","enrollment":30},{"nctId":"NCT04382404","phase":"PHASE1","title":"Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir","status":"COMPLETED","sponsor":"Catherine Anne Chappell","startDate":"2020-10-22","conditions":"Hepatitis C, Chronic","enrollment":11},{"nctId":"NCT05717400","phase":"PHASE4","title":"Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-03-17","conditions":"Liver Cancer","enrollment":2},{"nctId":"NCT06533319","phase":"NA","title":"Hepatitis C Treatment in Idaho County Jails","status":"NOT_YET_RECRUITING","sponsor":"Eastern Idaho Public Health","startDate":"2024-08-01","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT03627546","phase":"NA","title":"HCV Seek, Test and Rapid Treatment for Young PWID","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2018-09-18","conditions":"Hepatitis C, Drug Use","enrollment":39},{"nctId":"NCT06306300","phase":"PHASE4","title":"Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2022-07-04","conditions":"Hepatitis C","enrollment":30000},{"nctId":"NCT06180590","phase":"","title":"The Efficacy of Vosevi in Treating DAA-experienced Patients","status":"RECRUITING","sponsor":"The Third Affiliated Hospital of Guangzhou Medical University","startDate":"2023-02-28","conditions":"Chronic Hepatitis C, Medication Reaction","enrollment":200},{"nctId":"NCT03570112","phase":"","title":"Transmission of Chronic Hepatitis C in Pregnancy","status":"COMPLETED","sponsor":"The Christ Hospital","startDate":"2018-06-08","conditions":"Hepatitis C, Pregnancy Complications, Vertical Disease Transmission","enrollment":40},{"nctId":"NCT05264558","phase":"PHASE4","title":"Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30%","status":"COMPLETED","sponsor":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd","startDate":"2022-07-25","conditions":"Hepatitis C","enrollment":606},{"nctId":"NCT05016609","phase":"PHASE4","title":"Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)","status":"UNKNOWN","sponsor":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd","startDate":"2022-03-09","conditions":"Hepatitis C","enrollment":1800},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT03801707","phase":"PHASE2, PHASE3","title":"Utilization of Hepatitis C Positive Kidneys in Negative Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2019-03-22","conditions":"Kidney Transplant, Hepatitis C, HCV","enrollment":54},{"nctId":"NCT05895448","phase":"PHASE4","title":"Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics","status":"UNKNOWN","sponsor":"Center For Hepatitis C, Atlanta, GA","startDate":"2018-03-01","conditions":"Chronic Hepatitis C, People Who Inject Drugs","enrollment":125},{"nctId":"NCT03823911","phase":"PHASE4","title":"Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-11-18","conditions":"Cardiovascular Diseases, Hepatitis C, Hiv","enrollment":87},{"nctId":"NCT03057847","phase":"PHASE4","title":"Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection","status":"COMPLETED","sponsor":"Elizabeth Krans, MD","startDate":"2018-01-30","conditions":"Hepatitis C, Chronic, Opioid-use Disorder","enrollment":32},{"nctId":"NCT03702218","phase":"EARLY_PHASE1","title":"Hepatitis C Positive Donor Into Hepatitis C Negative Recipients","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2019-07-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT03625687","phase":"PHASE4","title":"Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-02-05","conditions":"Respiratory Failure, Hepatitis C","enrollment":19},{"nctId":"NCT03724149","phase":"PHASE1, PHASE2","title":"Transplanting Hepatitis C Lungs Into Negative Lung Recipients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-12-12","conditions":"Lung Diseases","enrollment":10},{"nctId":"NCT04653818","phase":"PHASE4","title":"HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2020-10-05","conditions":"Hepatocellular Carcinoma, Hepatitis C, Neoplasm Recurrence","enrollment":84},{"nctId":"NCT02836925","phase":"PHASE2","title":"Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2016-03","conditions":"Indolent B-cell Lymphoma, Hepatitis C","enrollment":40},{"nctId":"NCT02510300","phase":"","title":"A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-10-21","conditions":"Hepatitis C Virus Infection","enrollment":461},{"nctId":"NCT03492112","phase":"NA","title":"A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-09-10","conditions":"Hepatitis C","enrollment":101},{"nctId":"NCT03377478","phase":"PHASE1","title":"Expanding the Pool in Lung Transplantation","status":"COMPLETED","sponsor":"Pablo Sanchez","startDate":"2019-07-30","conditions":"Hepatitis C, Lung Transplant","enrollment":10},{"nctId":"NCT03086044","phase":"PHASE4","title":"Transplanting Hepatitis C Positive Organs","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2017-03-01","conditions":"Hepatitis C, Awaiting Organ Transplant","enrollment":148},{"nctId":"NCT05503979","phase":"","title":"Elimination of Hepatitis C Virus Among Users of Substances","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2022-11-15","conditions":"Hepatitis C in Substance Users","enrollment":1000},{"nctId":"NCT04695769","phase":"PHASE4","title":"Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders","status":"COMPLETED","sponsor":"Helwan University","startDate":"2020-11-21","conditions":"Chronic Hepatitis C","enrollment":281},{"nctId":"NCT03208127","phase":"PHASE4","title":"DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2017-11-21","conditions":"End Stage Liver Disease, Hepatitis C","enrollment":33},{"nctId":"NCT05474781","phase":"","title":"Eliminating HCV Infection Among PWUD","status":"UNKNOWN","sponsor":"Vancouver Infectious Diseases Centre","startDate":"2019-02-22","conditions":"Hepatitis C, Chronic, Drug Use","enrollment":300},{"nctId":"NCT05467826","phase":"PHASE4","title":"Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-09-01","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":"Chronic Hepatitis C Infection","enrollment":1128},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT04112303","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-10-16","conditions":"Hepatitis C Virus Infection","enrollment":37},{"nctId":"NCT03776760","phase":"","title":"Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination","status":"UNKNOWN","sponsor":"Kirby Institute","startDate":"2019-05-28","conditions":"Hepatitis C, Hepatitis, Liver Diseases","enrollment":600},{"nctId":"NCT02745535","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2016-05","conditions":"Chronic Hepatitis C","enrollment":77},{"nctId":"NCT02938013","phase":"PHASE4","title":"deLIVER: Direct Acting Antiviral Effects on the Liver","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-01","conditions":"HCV Coinfection, Liver Disease, HIV","enrollment":15},{"nctId":"NCT03512210","phase":"PHASE4","title":"Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2018-10-22","conditions":"Hepatitis C, HIV-1-infection, Liver Diseases","enrollment":400},{"nctId":"NCT02625909","phase":"PHASE3","title":"Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2017-03-09","conditions":"Hepatitis C","enrollment":222},{"nctId":"NCT05092074","phase":"","title":"Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2021-10-01","conditions":"Hepatitis C Virus Infection, Treatment Side Effects, Adherence, Treatment","enrollment":100},{"nctId":"NCT04211909","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-01-03","conditions":"Hepatitis C Virus Infection","enrollment":87},{"nctId":"NCT04039698","phase":"NA","title":"Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2019-08-23","conditions":"Chronic Hepatitis C","enrollment":144},{"nctId":"NCT04997564","phase":"PHASE4","title":"The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2021-08","conditions":"Chronic Hepatitis C, Chronic Hepatitis B","enrollment":120},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":"Hepatitis C, Chronic","enrollment":300},{"nctId":"NCT03818308","phase":"PHASE2","title":"Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2019-05-28","conditions":"Hepatitis C, Acute Hepatitis C","enrollment":20},{"nctId":"NCT04948801","phase":"","title":"SOF/VEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-12-08","conditions":"Hepatitis C","enrollment":150},{"nctId":"NCT03235154","phase":"PHASE4","title":"A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2017-10-11","conditions":"Hepatitis C, Chronic, Hepatitis C, Opiate Dependence","enrollment":11},{"nctId":"NCT03501550","phase":"PHASE2","title":"Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)","status":"COMPLETED","sponsor":"Cocrystal Pharma, Inc.","startDate":"2018-06-26","conditions":"Chronic Hepatitis C","enrollment":12},{"nctId":"NCT03619837","phase":"PHASE4","title":"Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-07-15","conditions":"Hepatitis C, Transplantation Disease Transmission","enrollment":122},{"nctId":"NCT02825212","phase":"PHASE2, PHASE3","title":"Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2016-02","conditions":"Hepatitis C, Cryoglobulinemia","enrollment":10},{"nctId":"NCT04664894","phase":"","title":"Direct Acting Anti-Viral's In Chronic HCV Patients","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2018-05-15","conditions":"Safety Issues","enrollment":511},{"nctId":"NCT04662138","phase":"","title":"Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2020-08-24","conditions":"Hepatitis C, Relapse, Antivirals","enrollment":100},{"nctId":"NCT03389061","phase":"PHASE4","title":"Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet","status":"WITHDRAWN","sponsor":"Radboud University Medical Center","startDate":"2018-04-01","conditions":"HCV","enrollment":""},{"nctId":"NCT03820258","phase":"PHASE2","title":"Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2019-01-28","conditions":"Hepatitis C Virus Infection","enrollment":21},{"nctId":"NCT03513393","phase":"PHASE1","title":"Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole.","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2018-08-01","conditions":"Hepatitis C, Swallowing Disorder","enrollment":11},{"nctId":"NCT03022981","phase":"PHASE2","title":"Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-01-26","conditions":"Hepatitis C Virus Infection","enrollment":216},{"nctId":"NCT02185794","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-06-13","conditions":"Hepatitis C Virus Infection","enrollment":101},{"nctId":"NCT02533427","phase":"PHASE1","title":"Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-10-29","conditions":"HCV Infection","enrollment":15},{"nctId":"NCT03891550","phase":"PHASE3","title":"Micro-elimination of Hepatitis C Virus Infection in Uremics","status":"UNKNOWN","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2019-05-13","conditions":"Hepatitis C","enrollment":135},{"nctId":"NCT03249194","phase":"EARLY_PHASE1","title":"Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2017-08-17","conditions":"Kidney Transplant, Hepatitis C","enrollment":25},{"nctId":"NCT02468648","phase":"PHASE2","title":"Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2015-06-09","conditions":"Chronic Hepatitis C","enrollment":72},{"nctId":"NCT03036852","phase":"PHASE2","title":"Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-03-22","conditions":"Chronic Hepatitis C","enrollment":59},{"nctId":"NCT02378935","phase":"PHASE2","title":"Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-02-17","conditions":"Hepatitis C Virus Infection","enrollment":205},{"nctId":"NCT02378961","phase":"PHASE2","title":"Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-02-16","conditions":"Hepatitis C Virus Infection","enrollment":128},{"nctId":"NCT02994056","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-01-23","conditions":"Hepatitis C Virus Infection","enrollment":32},{"nctId":"NCT03313414","phase":"PHASE4","title":"HCV Post-Exposure Prophylaxis for Health Care Workers","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-08-13","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT03549312","phase":"PHASE4","title":"Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy","status":"UNKNOWN","sponsor":"Saskatchewan Health Authority - Regina Area","startDate":"2018-02-01","conditions":"HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence","enrollment":25},{"nctId":"NCT02064049","phase":"PHASE4","title":"Surveillance and Treatment of Prisoners With Hepatitis C","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2014-10","conditions":"Hepatitis C","enrollment":3692},{"nctId":"NCT03207399","phase":"PHASE4","title":"Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment","status":"TERMINATED","sponsor":"Duke University","startDate":"2017-09-15","conditions":"Hepatitis C, Chronic, Lung Transplant","enrollment":1},{"nctId":"NCT03888729","phase":"PHASE4","title":"Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)","status":"UNKNOWN","sponsor":"Partners in Health","startDate":"2019-08-26","conditions":"Hepatitis C, Chronic","enrollment":100},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT03579576","phase":"","title":"Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar","status":"COMPLETED","sponsor":"Right to Care","startDate":"2017-12-20","conditions":"Hepatitis C, Hepatitis B, HIV Infections","enrollment":803},{"nctId":"NCT03118843","phase":"PHASE3","title":"Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-04-25","conditions":"Hepatitis C Virus Infection","enrollment":31},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT03074331","phase":"PHASE3","title":"Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-03-23","conditions":"Hepatitis C Virus Infection","enrollment":130},{"nctId":"NCT02607735","phase":"PHASE3","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"Hepatitis C","enrollment":416},{"nctId":"NCT02639247","phase":"PHASE3","title":"Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-23","conditions":"Hepatitis C Virus Infection","enrollment":333},{"nctId":"NCT02607800","phase":"PHASE3","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-16","conditions":"Hepatitis C","enrollment":943},{"nctId":"NCT02639338","phase":"PHASE3","title":"Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-23","conditions":"Hepatitis C Virus Infection","enrollment":220},{"nctId":"NCT02336139","phase":"PHASE2","title":"A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2016-03-16","conditions":"Hepatitis C","enrollment":103},{"nctId":"NCT02996682","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-12-26","conditions":"Hepatitis C Virus Infection","enrollment":102},{"nctId":"NCT02536313","phase":"PHASE2","title":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-07-29","conditions":"Hepatitis C Virus Infection","enrollment":49},{"nctId":"NCT02728206","phase":"PHASE2","title":"Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-06-12","conditions":"Hepatitis C Virus Infection","enrollment":9}],"_emaApprovals":[],"_faersSignals":[{"count":858,"reaction":"FATIGUE"},{"count":720,"reaction":"HEADACHE"},{"count":387,"reaction":"PRODUCT DOSE OMISSION ISSUE"},{"count":384,"reaction":"NAUSEA"},{"count":206,"reaction":"INTENTIONAL DOSE OMISSION"},{"count":190,"reaction":"DIARRHOEA"},{"count":168,"reaction":"DEATH"},{"count":150,"reaction":"PRODUCT DOSE OMISSION"},{"count":148,"reaction":"INSOMNIA"},{"count":127,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":500,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epclusa"],"phase":"marketed","status":"active","brandName":"Sofosbuvir / Velpatasvir","genericName":"Sofosbuvir / Velpatasvir","companyName":"Peking University First Hospital","companyId":"peking-university-first-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sofosbuvir inhibits hepatitis C virus NS5B polymerase while velpatasvir inhibits NS5A protein, together blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, all genotypes, HCV in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}